Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain OPHT message board posts where the ticker symbol OPHT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest OPHT SEC Filings

Filings Format Description Filed/Effective File/Film Number
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-053125 (34 Act)  Size: 43 KB
2018-08-22 001-36080
EFFECT  Documents Notice of Effectiveness
Acc-no: 9999999995-18-002115 (33 Act)  Size: 1 KB
2018-08-15 16:30:00 333-226497
UPLOAD  Documents [Cover]SEC-generated letter
Acc-no: 0000000000-18-025062 Size: 44 KB
CORRESP  Documents [Cover]Correspondence
Acc-no: 0001104659-18-051535 Size: 7 KB
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-007238 (34 Act)  Size: 17 KB
2018-08-10 001-36080
S-3  Documents Registration statement under Securities Act of 1933
Acc-no: 0001047469-18-005356 (33 Act)  Size: 1 MB
2018-08-01 333-226497
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001410939-18-000047 (34 Act)  Size: 6 MB
2018-08-01 001-36080
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001410939-18-000044 (34 Act)  Size: 154 KB
2018-08-01 001-36080
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-042364 Size: 5 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-044691 Size: 5 KB
More OPHT SEC Filings

Related news from
Wed, 12 Sep 2018
19:11:30 +0000
Is Ophthotech Corporation (NASDAQ:OPHT) Attractive At Its Current PE Ratio?
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...
Fri, 31 Aug 2018
15:38:03 +0000
Why Is Ophthotech (OPHT) Up 5.8% Since Last Earnings Report?
Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wed, 22 Aug 2018
11:30:00 +0000
Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published in Proceedings of the National Academy of Sciences
Ophthotech Corporation (OPHT) announced today that scientists at the University of Pennsylvania (Penn) and University of Florida published proof-of-concept study results on an adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) licensed by Ophthotech. In June 2018, Ophthotech announced that it entered into an exclusive global license agreement with the University of Florida Research Foundation and Penn for rights to develop and commercialize this novel AAV gene therapy product candidate for the treatment of RHO-adRP.
Fri, 17 Aug 2018
21:40:41 +0000
Edited Transcript of OPHT earnings conference call or presentation 1-Aug-18 12:00pm GMT
Q2 2018 Ophthotech Corp Earnings Call
Mon, 13 Aug 2018
11:50:00 +0000
Report: Developing Opportunities within Energy Recovery, Lamb Weston, Neurocrine Biosciences, Pioneer Natural Resources, Meritor, and Ophthotech — Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Energy ...
Thu, 02 Aug 2018
14:35:02 +0000
Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track
Ophthotech reports narrower-than-expected loss in the second quarter.
Wed, 01 Aug 2018
11:27:24 +0000
Ophthotech: 2Q Earnings Snapshot
The New York-based company said it had a loss of 37 cents per share. The company's shares closed at $2.49. A year ago, they were trading at $2.40. _____ This story was generated by Automated Insights ( ...
Wed, 01 Aug 2018
11:15:00 +0000
Ophthotech Reports Second Quarter 2018 Financial and Operating Results
Ophthotech Reports Second Quarter 2018 Financial and Operating Results
Wed, 01 Aug 2018
10:00:00 +0000
Ophthotech Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Ophthotech Corp. (NASDAQ: OPHT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 8:00 AM Eastern Time. To ...
Tue, 31 Jul 2018
23:31:00 +0000
Robbins Arroyo LLP: Ophthotech Corporation (OPHT) Misled Shareholders According to a Consolidated Amended Class Action Complaint
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Ophthotech Corporation (OPHT) filed a consolidated amended class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 2, 2015 and December 12, 2016. Ophthotech, a biopharmaceutical company, develops novel therapeutics to treat ophthalmic diseases. The company's most advanced product candidate was Fovista, an anti-platelet derived growth factor agent designed to treat wet age-related macular generation ("AMD").
Wed, 25 Jul 2018
20:05:00 +0000
Ophthotech Corporation to Report Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 1, 2018
Ophthotech Corporation (OPHT) today announced that it will report its second quarter 2018 financial and operating results on Wednesday, August 1, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Ophthotech website at:
Tue, 17 Jul 2018
11:25:00 +0000
Free Technical Research on OPKO Health and Three More Biotech Equities
On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, assessed the following Biotechnology equities this morning: Onconova Therapeutics Inc. (NASDAQ: ONTX), Ophthotech Corp. (NASDAQ: OPHT), OPKO Health Inc. (NASDAQ: OPK), and OvaScience Inc. (NASDAQ: OVAS).
Tue, 10 Jul 2018
12:00:00 +0000
electroCore, Inc. Announces Additions to Board of Directors in Connection with Recently Completed Initial Public Offering
BASKING RIDGE, N.J., July 10, 2018-- electroCore, Inc., a commercial-stage bioelectronic medicine company, today announced the appointment of Carrie S. Cox as Chairman of its Board of Directors, and Michael ...
Fri, 08 Jun 2018
12:41:12 +0000
Ophthotech (OPHT) Soars: Stock Adds 10.4% in Session
Ophthotech (OPHT) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Fri, 08 Jun 2018
12:00:00 +0000
Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Ophthotech Corporation
NEW YORK, NY / ACCESSWIRE / June 8, 2018 / While Proteostasis Therapeutics announced positive results from an ongoing 14-day dosing study of PTI-801, an analyst at RBC Capital Markets didn't seem impressed and downgraded the company this week as well as lowered his price target on shares. Ophthotech Corporation saw a different story yesterday, gaining over 10% after announcing that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania. The results had shown statistically significant improvement in sweat chloride, body mass index, and weight and blood glucose.
Thu, 07 Jun 2018
11:00:00 +0000
Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania
Ophthotech Corporation (OPHT) announced today that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania (Penn) to develop and commercialize a novel adeno-associated virus (AAV) gene therapy product for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), an orphan monogenic disease that is characterized by progressive and severe loss of vision leading to blindness. Preclinical anatomical and functional proof-of-concept studies have demonstrated promising results in a canine disease model. In addition to the exclusive license agreement, Ophthotech and Penn have also entered into a master sponsored research agreement, facilitated by the Penn Center for Innovation (PCI), pursuant to which Ophthotech and Penn plan to conduct preclinical and natural history studies.
Wed, 16 May 2018
03:52:15 +0000
Edited Transcript of OPHT earnings conference call or presentation 9-May-18 12:00pm GMT
Q1 2018 Ophthotech Corp Earnings Call
Thu, 10 May 2018
14:41:02 +0000
Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus
Ophthotech (OPHT) reports narrower year-over-year loss for the first quarter.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "The collective wisdom of the members and distributed in an unselfish manner is what I find to be the most valuable asset of the group." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards